Agency Forms Undergoing Paperwork Reduction Act Review, 2704-2706 [2025-00454]

Download as PDF 2704 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. 30341–3717. Telephone: (404) 718– 7664; Email: CBarrett@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2025–00492 Filed 1–10–25; 8:45 am] BILLING CODE 4163–18–P [FR Doc. 2025–00488 Filed 1–10–25; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention ddrumheller on DSK120RN23PROD with NOTICES1 Notice of Closed Meeting Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, pursuant to Public Law 92– 463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— DP25–041, Connecting Organizations and People to Empower Diabetes Prevention and Treatment (Connections). Date: March 11, 2025. Time: 10 a.m.–6 p.m., EDT. Place: Teleconference/Web Conference. Agenda: To review and evaluate grant applications. For Further Information Contact: Catherine Barrett, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop S106–3, Atlanta, Georgia VerDate Sep<11>2014 18:48 Jan 09, 2025 Jkt 265001 Notice of Closed Meeting Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, pursuant to Public Law 92– 463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— RFA–OH–24–002, Exploratory/ Developmental Grants on Lifestyle Medicine Research Related to the World Trade Center Health Program (R21); RFA–OH–24–003, Exploratory/ Developmental Grants Related to the World Trade Center Survivors (R21-No Applications with Responders Accepted); RFA–OH–24–004, World Trade Center Health Program Mentored Research Scientist Career Development Award (K01); and RFA–OH–25–001, Exploratory/Developmental Research for World Trade Center Health Program Evidence-based Strategies to Improve Treatment Effectiveness, Diagnostic PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 Practices, and Program Evaluation (R21). Dates and Times: February 25, 2025, 9 a.m.–5 p.m., EST; and February 26, 2025, 9 a.m.–12 p.m., EST. Place: Courtyard by Marriott Atlanta Decatur Downtown/Emory, 130 Clairemont Avenue, Decatur, Georgia 30030. Agenda: To review and evaluate grant applications. For Further Information Contact: Laurel Garrison, M.P.H., Scientific Review Officer, Office of Extramural Coordination and Special Projects, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 5555 Ridge Avenue, Cincinnati, Ohio 45213. Telephone: (513) 533–8324; Email: LGarrison@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2025–00487 Filed 1–10–25; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–25–1385] Agency Forms Undergoing Paperwork Reduction Act Review In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled ‘‘Characteristics of Cases of Priority Fungal Diseases’’ to the Office of Management and Budget (OMB) for review and approval. CDC previously published a ‘‘Proposed Data Collection Submitted for Public Comment and Recommendations’’ notice on October 25, 2024, to obtain comments from the public and affected agencies. CDC did not receive comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments. E:\FR\FM\13JAN1.SGM 13JAN1 2705 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs. To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/ do/PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication. Proposed Project Characteristics of Cases of Priority Fungal Diseases (OMB Control No. 0920–1385, Exp. 4/30/2027)— Revision—National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC). Background and Brief Description Fungal diseases cause substantial illness, ranging from mild infection to severe or life-threatening invasive disease. They also constitute a considerable financial burden on patients and healthcare systems. Awareness of fungal diseases is low, and data collection has historically been limited in size, scope, and coordination, which has hindered our understanding of these diseases. Detailed epidemiologic and clinical data are critical to inform appropriate public health responses. We plan to enhance surveillance of high priority fungal diseases across the United States to better characterize factors such as disease burden, geographic scope, patient risk factors, health disparities, healthcare utilization, outcomes, and emerging trends. This project will serve as a Revision of the information collections project: Characteristics of Cases of Priority Fungal Diseases Case Report Form (CRF) (OMB Control No. 0920–1385). The Revision will expand the number of fungal diseases for which data may be collected. In addition to triazole-resistant A. fumigatus infections, coccidioidomycosis, histoplasmosis, blastomycosis, C. auris, and antifungalresistant dermatophytosis, CRFs have also been developed for chromoblastomycosis, mycetoma, and sporotrichosis. We plan to use standardized CRFs to collect public health surveillance data for cases of these diseases regarding demographics (e.g., age, sex, race/ethnicity, location of residence), underlying medical conditions, diagnosis (e.g., clinical presentation, laboratory testing), treatments, and outcomes (e.g., hospitalization, vital status). The corresponding CRF would be filled out voluntarily by State, local or Tribal health departments, Federal agencies, and the members of the private sector (e.g., academic institutions) and contains a section for medical chart review and an optional supplemental interview (including data on potential occupational or environmental exposures) of the patient or their representative. Findings can help identify populations at higher risk of these diseases, detect emerging epidemiologic trends, and guide prevention and response efforts. They can also help better focus public and healthcare provider outreach, inform efforts to contain or mitigate spread, and influence health policy and research on prevention and treatment. CDC requests OMB approval for an estimated 1,564 annual burden hours. There is no cost to respondents other than their time to participate. ESTIMATED ANNUALIZED BURDEN HOURS Form name Type of respondent Triazole-resistant Aspergillus fumigatus Case Report Form (Attachment 3a). Coccidioidomycosis Case Report Form (Attachment 3b) ............ State and Local Health Departments. State and Local Health Departments. Private Sectors ................. State and Local Health Departments. Private Sectors ................. State and Local Health Departments. Private Sectors ................. State and Local Health Departments. Private Sectors ................. State and Local Health Departments. Private Sectors ................. Private Sectors ................. Private Sectors ................. Histoplasmosis Case Report Form (Attachment 3c) .................... ddrumheller on DSK120RN23PROD with NOTICES1 Blastomycosis Case Report Form (Attachment 3d) ..................... Candida auris Case Report Form (Attachment 3e) ..................... Antifungal-resistant dermatophytosis case report form (Attachment 3f). Chromoblastomycosis case report form (Attachment 3g) ............ Mycetoma case report form (Attachment 3h) ............................... Sporotrichosis case report form (Attachment 3i) .......................... VerDate Sep<11>2014 18:48 Jan 09, 2025 Jkt 265001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 Number of respondents E:\FR\FM\13JAN1.SGM Number responses per respondent Avg. burden per response (in hrs.) 15 15 0.5 10 25 1.0 3 10 10 25 1.0 1.0 3 10 10 25 1.0 1.0 3 15 10 20 1.0 0.75 3 10 10 10 0.75 0.5 25 25 25 10 5 10 0.5 0.5 0.5 13JAN1 2706 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2025–00454 Filed 1–10–25; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–3469–PN] Medicare and Medicaid Programs: Application From The Joint Commission for Continued Approval of its Hospice Accreditation Program Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice with request for comment. AGENCY: This proposed notice acknowledges the receipt of an application from The Joint Commission for continued recognition as a national accrediting organization for hospices that wish to participate in the Medicare or Medicaid programs. DATES: To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on February 12, 2025. ADDRESSES: In commenting, refer to file code CMS–3469–PN. Comments, including mass comment submissions, must be submitted in one of the following three ways (please choose only one of the ways listed): 1. Electronically. You may submit electronic comments on this regulation to https://www.regulations.gov . Follow the ‘‘Submit a comment’’ instructions. 2. By regular mail. You may mail written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3469– PN, P.O. Box 8010, Baltimore, MD 21244–8010. Please allow sufficient time for mailed comments to be received before the close of the comment period. 3. By express or overnight mail. You may send written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3469– PN, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850. FOR FURTHER INFORMATION CONTACT: Lillian Williams, (410) 786–8636 or Melissa Rice, (410) 786–3270. ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 18:48 Jan 09, 2025 Jkt 265001 SUPPLEMENTARY INFORMATION: Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: https:// www.regulations.gov. Follow the search instructions on that website to view public comments. CMS will not post on Regulations.gov public comments that make threats to individuals or institutions or suggest that the commenter will take actions to harm an individual. CMS continues to encourage individuals not to submit duplicative comments. We will post acceptable comments from multiple unique commenters even if the content is identical or nearly identical to other comments. I. Background Under the Medicare program, eligible beneficiaries may receive covered services in a hospice, provided that certain requirements are met by the hospice. Section 1861(dd) of the Social Security Act (the Act) establishes distinct criteria for facilities seeking designation as a hospice. Regulations concerning provider agreements are at 42 CFR part 489 and those pertaining to activities relating to the survey and certification of facilities are at 42 CFR part 488. The regulations at 42 CFR part 418 specify the conditions that a hospice must meet in order to participate in the Medicare program, the scope of covered services and the conditions for Medicare payment for hospice services. Generally, to enter into an agreement, a hospice must first be certified by a state survey agency (SA) as complying with the conditions or requirements set forth in part 418. Thereafter, the hospice is subject to regular surveys by a SA to determine whether it continues to meet these requirements. However, section 1865(a)(1) of the Act provides that, if a provider entity demonstrates through accreditation by a Centers for Medicare & Medicaid Services (CMS) approved national Accrediting Organization (AO) that all applicable Medicare conditions are met or exceeded, we will deem those provider entities as having met the requirements. Accreditation by an AO is voluntary and is not required for Medicare participation. If an AO is recognized by the Secretary of the Department of Health PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 and Human Services (the Secretary) as having standards for accreditation that meet or exceed Medicare requirements, any provider entity accredited by the national accrediting body’s approved program would be deemed to meet the Medicare conditions. A national AO applying for approval of its accreditation program under part 488, subpart A, must provide CMS with reasonable assurance that the AO requires the accredited provider entities to meet requirements that are at least as stringent as the Medicare conditions. Our regulations concerning the approval of AOs are set forth at §§ 488.4 and 488.5. The regulations at § 488.5(e)(2)(i) require AOs to reapply for continued approval of its accreditation program every 6 years or sooner as determined by CMS. The Joint Commission’s (TJC’s) current term of approval for their hospice accreditation program expires June 18, 2025. II. Approval of Deeming Organizations Section 1865(a)(2) of the Act and our regulations at § 488.5 require that our findings concerning review and approval of a national AO’s requirements consider, among other factors, the applying AO’s requirements for accreditation; survey procedures; resources for conducting required surveys; capacity to furnish information for use in enforcement activities; monitoring procedures for provider entities found not in compliance with the conditions or requirements; and ability to provide CMS with the necessary data for validation. Section 1865(a)(3)(A) of the Act further requires that we publish, within 60 days of receipt of an organization’s complete application, a notice identifying the national accrediting body making the request, describing the nature of the request, and providing at least a 30-day public comment period. We have 210 days from the receipt of a complete application to publish notice of approval or denial of the application. The purpose of this proposed notice is to inform the public of TJC’s request for continued approval of its hospice accreditation program. This notice also solicits public comment on whether TJC’s requirements meet or exceed the Medicare conditions of participation (CoPs) for hospices. III. Evaluation of Deeming Authority Request TJC submitted all the necessary materials to enable us to make a determination concerning its request for continued approval of its hospice accreditation program. This application E:\FR\FM\13JAN1.SGM 13JAN1

Agencies

[Federal Register Volume 90, Number 7 (Monday, January 13, 2025)]
[Notices]
[Pages 2704-2706]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00454]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-25-1385]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled ``Characteristics of Cases of Priority Fungal 
Diseases'' to the Office of Management and Budget (OMB) for review and 
approval. CDC previously published a ``Proposed Data Collection 
Submitted for Public Comment and Recommendations'' notice on October 
25, 2024, to obtain comments from the public and affected agencies. CDC 
did not receive comments related to the previous notice. This notice 
serves to allow an additional 30 days for public and affected agency 
comments.

[[Page 2705]]

    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570. Comments and recommendations for the proposed 
information collection should be sent within 30 days of publication of 
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular 
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct 
written comments and/or suggestions regarding the items contained in 
this notice to the Attention: CDC Desk Officer, Office of Management 
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 
395-5806. Provide written comments within 30 days of notice 
publication.

Proposed Project

    Characteristics of Cases of Priority Fungal Diseases (OMB Control 
No. 0920-1385, Exp. 4/30/2027)--Revision--National Center for Emerging 
and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control 
and Prevention (CDC).

Background and Brief Description

    Fungal diseases cause substantial illness, ranging from mild 
infection to severe or life-threatening invasive disease. They also 
constitute a considerable financial burden on patients and healthcare 
systems. Awareness of fungal diseases is low, and data collection has 
historically been limited in size, scope, and coordination, which has 
hindered our understanding of these diseases. Detailed epidemiologic 
and clinical data are critical to inform appropriate public health 
responses. We plan to enhance surveillance of high priority fungal 
diseases across the United States to better characterize factors such 
as disease burden, geographic scope, patient risk factors, health 
disparities, healthcare utilization, outcomes, and emerging trends. 
This project will serve as a Revision of the information collections 
project: Characteristics of Cases of Priority Fungal Diseases Case 
Report Form (CRF) (OMB Control No. 0920-1385). The Revision will expand 
the number of fungal diseases for which data may be collected.
    In addition to triazole-resistant A. fumigatus infections, 
coccidioidomycosis, histoplasmosis, blastomycosis, C. auris, and 
antifungal-resistant dermatophytosis, CRFs have also been developed for 
chromoblastomycosis, mycetoma, and sporotrichosis. We plan to use 
standardized CRFs to collect public health surveillance data for cases 
of these diseases regarding demographics (e.g., age, sex, race/
ethnicity, location of residence), underlying medical conditions, 
diagnosis (e.g., clinical presentation, laboratory testing), 
treatments, and outcomes (e.g., hospitalization, vital status). The 
corresponding CRF would be filled out voluntarily by State, local or 
Tribal health departments, Federal agencies, and the members of the 
private sector (e.g., academic institutions) and contains a section for 
medical chart review and an optional supplemental interview (including 
data on potential occupational or environmental exposures) of the 
patient or their representative.
    Findings can help identify populations at higher risk of these 
diseases, detect emerging epidemiologic trends, and guide prevention 
and response efforts. They can also help better focus public and 
healthcare provider outreach, inform efforts to contain or mitigate 
spread, and influence health policy and research on prevention and 
treatment.
    CDC requests OMB approval for an estimated 1,564 annual burden 
hours. There is no cost to respondents other than their time to 
participate.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                      Number        Avg. burden
               Form name                   Type of respondent        Number of     responses per   per response
                                                                    respondents     respondent       (in hrs.)
----------------------------------------------------------------------------------------------------------------
Triazole-resistant Aspergillus          State and Local Health                15              15             0.5
 fumigatus Case Report Form              Departments.
 (Attachment 3a).
Coccidioidomycosis Case Report Form     State and Local Health                10              25             1.0
 (Attachment 3b).                        Departments.
                                        Private Sectors.........               3              10             1.0
Histoplasmosis Case Report Form         State and Local Health                10              25             1.0
 (Attachment 3c).                        Departments.
                                        Private Sectors.........               3              10             1.0
Blastomycosis Case Report Form          State and Local Health                10              25             1.0
 (Attachment 3d).                        Departments.
                                        Private Sectors.........               3              10             1.0
Candida auris Case Report Form          State and Local Health                15              20            0.75
 (Attachment 3e).                        Departments.
                                        Private Sectors.........               3              10            0.75
Antifungal-resistant dermatophytosis    State and Local Health                10              10             0.5
 case report form (Attachment 3f).       Departments.
Chromoblastomycosis case report form    Private Sectors.........              25              10             0.5
 (Attachment 3g).
Mycetoma case report form (Attachment   Private Sectors.........              25               5             0.5
 3h).
Sporotrichosis case report form         Private Sectors.........              25              10             0.5
 (Attachment 3i).
----------------------------------------------------------------------------------------------------------------



[[Page 2706]]

Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health 
Ethics and Regulations, Office of Science, Centers for Disease Control 
and Prevention.
[FR Doc. 2025-00454 Filed 1-10-25; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.